Nivagen Raises Cash To Fuel Growth

More Financing In The Works, CEO Says

California-based Nivagen is continuing to raise money to push through a number of generic launches in the US this year, the company’s founder and chief Jay Shukla told Generics Bulletin.

US_Dollars
Another round of financing by Nivagen will help push generics through this year. • Source: Shutterstock

North American generics specialist Nivagen Pharmaceuticals has secured an $8m credit facility with help from commercial finance advisors Business Capital, providing some of the firepower to launch almost 10 new generics this year.

The debt, which is secured on assets, will hand the firm “the necessary working capital to facilitate its growth as well as help fund certain development costs associated

More from Deals

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By 

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By 

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By 

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By 

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By 

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By 

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.